Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Annual CT Screening Offers Big Mortality Benefit To Smokers – NCI

This article was originally published in The Gray Sheet

Executive Summary

Annual screening of current and former heavy smokers with computed tomography can reduce their risk of dying from lung cancer by about 20%, according to a large National Cancer Institute-backed study.
Advertisement

Related Content

CT Lung Cancer Screening Is Up For National Medicare Coverage Consideration
USPSTF Recommends Low-Dose CT Lung Cancer Screening For People At High Risk
CT’s Benefits Outweigh Risks In Some 55-And-Older Smokers, Societies Find
Research In Brief
Sanovas Preps 510(k) For Micro Catheter Targeting Pulmonary Disease
Research In Brief
Devices Rank Front And Center In Cleveland Clinic’s 'Top 10' Picks
Devices Rank Front And Center In Cleveland Clinic’s 'Top 10' Picks
Lung Cancer Screening Bill Calls For CT Quality Standards
Better Imaging Doesn't Always Mean Better Diagnosis, Expert Says

Topics

Advertisement
UsernamePublicRestriction

Register

MT029558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel